Piramal Pharma Stock Screener | Share Price & Fundamental Analysis
PPLPHARMA
Pharmaceuticals
Screen Piramal Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹180.00
▲
1.14 (0.64%)
Share Price BSE
₹180.05
▲
1.15 (0.64%)
Market Cap
₹24,416.96 Cr.
P/E Ratio (TTM)
-1000.28
P/B Ratio
2.96
EPS (TTM)
₹0.69
Dividend Yield
0.08%
Debt to Equity
0.60
52W High
₹242.30
52W Low
₹166.52
Operating Margin
20.00%
Profit Margin
5.48%
Revenue (TTM)
₹2,812.00
EBITDA
₹619.00
Net Income
₹154.00
Total Assets
₹15,678.00
Total Equity
₹8,126.00
Piramal Pharma Share Price History - Stock Screener Chart
Screen PPLPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Piramal Pharma Company Profile - Fundamental Screener
Screen Piramal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PPLPHARMA shares.
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Nandini Piramal
ISIN
INE0DK501011
Website
https://www.piramalpharma.com
Piramal Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen PPLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 15,678 | 15,312 | 14,523 | 12,797 | 10,900 |
| Current Assets | 5,797 | 5,465 | 4,836 | 4,067 | 3,649 |
| Fixed Assets | 8,133 | 7,990 | 7,469 | 6,879 | 6,106 |
| Liabilities | |||||
| Total Liabilities | 15,678 | 15,312 | 14,523 | 12,797 | 10,900 |
| Current Liabilities | 3,786 | 3,031 | 3,906 | 3,067 | 2,805 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 8,126 | 7,911 | 6,774 | 6,697 | 5,605 |
| Share Capital | 1,324 | 1,323 | 1,193 | 1,186 | 995 |
| Reserves & Surplus | 6,801 | 6,588 | 5,580 | 5,511 | 4,610 |
Screen PPLPHARMA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,812 | 2,031 | 2,124 | 2,591 | 1,993 | 2,320 | 2,233 | 2,196 | 1,802 | 1,980 | 2,034 | 2,229 | 1,574 | 1,777 | 1,814 |
| Expenses | 2,193 | 1,827 | 1,885 | 2,053 | 1,747 | 1,900 | 1,867 | 1,812 | 1,617 | 1,646 | 1,723 | 1,733 | 1,465 | 1,554 | 1,629 |
| EBITDA | 619 | 204 | 239 | 538 | 246 | 420 | 367 | 384 | 185 | 334 | 312 | 495 | 109 | 223 | 185 |
| Operating Profit % | 20.00% | 6.00% | 8.00% | 20.00% | 10.00% | 15.00% | 15.00% | 16.00% | 8.00% | 14.00% | 12.00% | 19.00% | 1.00% | 10.00% | 5.00% |
| Depreciation | 243 | 197 | 203 | 196 | 185 | 192 | 197 | 184 | 174 | 185 | 186 | 165 | 162 | 166 | 164 |
| Interest | 104 | 86 | 82 | 114 | 107 | 108 | 103 | 104 | 119 | 110 | 106 | 57 | 62 | 83 | 95 |
| Profit Before Tax | 273 | -79 | -46 | 228 | -45 | 120 | 67 | 95 | -107 | 40 | 19 | 273 | -115 | -26 | -74 |
| Tax | 119 | 3 | 53 | 126 | 44 | 98 | 63 | 45 | -9 | 35 | 9 | 69 | -6 | 11 | 17 |
| Net Profit | 154 | -82 | -99 | 101 | -89 | 23 | 4 | 50 | -99 | 5 | 10 | 204 | -109 | -37 | -90 |
| EPS | 1.16 | -0.62 | -0.75 | 0.77 | -0.67 | 0.17 | 0.03 | 0.42 | -0.83 | 0.04 | 0.08 | 1.72 | -0.92 | -0.31 | -0.76 |
Piramal Pharma Cash Flow Screener - Liquidity Fundamentals
Screen PPLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | 892 | 1,005 | 484 | 766 | 598 |
| Investing Activities | -488 | -416 | -1,334 | -1,737 | -4,464 |
| Financing Activities | -441 | -422 | 818 | 794 | 3,977 |
| Net Cash Flow | -37 | 166 | -32 | -177 | 110 |
Screen PPLPHARMA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 34.95% | 34.86% | 34.86% | 35.02% | 34.95% | 34.95% | 34.95% | 34.79% |
| FII Holding | 31.49% | 30.86% | 30.27% | 30.59% | 31.42% | 31.73% | 31.68% | 20.00% |
| DII Holding | 14.78% | 14.26% | 14.89% | 12.12% | 12.95% | 13.81% | 14.10% | 4.99% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.11% | 14.07% | 14.12% | 15.13% | 13.94% | 13.29% | 13.29% | 13.94% |
| Other Holding | 5.66% | 5.95% | 5.86% | 7.14% | 6.74% | 6.22% | 5.98% | 26.29% |
| Shareholder Count | 432,843 | 458,430 | 462,511 | 297,996 | 306,398 | 359,751 | 418,442 | 241,359 |
Piramal Pharma Dividend Screener - Share Yield Analysis
Screen PPLPHARMA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.14 | 0.08% |
| 2024-March | ₹0.11 | 0.05% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.56 | 0.84% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Piramal Pharma Index Membership - Market Screener Classification
Screen PPLPHARMA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Piramal Pharma Market Events Screener - Corporate Actions
Screen PPLPHARMA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | -1.56% |
| 2025-07-30 | 2025-07-30 | Annual General Meeting | NA | 2.83% |
| 2025-07-28 | 2025-07-28 | Quarterly Result Announcement | NA | -6.75% |
| 2025-07-16 | 2025-07-16 | Dividend | ₹ 0.14 /share | 0.61% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -0.02% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | 1.24% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | -2.78% |
| 2024-07-26 | 2024-07-26 | Annual General Meeting | NA | 5.86% |
| 2024-07-12 | 2024-07-12 | Dividend | ₹ 0.11 /share | 2.40% |
| 2023-08-02 | 2023-08-02 | Rights | 5:46 | 1.87% |
Piramal Pharma Competitors Screener - Peer Comparison
Screen PPLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,274 | 40.28 | 54,729 | 9.71% | 10,980 | 53.13 |
| Divis Laboratories | 177,545 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 136,055 | 62.26 | 11,539 | 6.99% | 1,911 | 71.28 |
| Cipla | 120,980 | 22.75 | 28,410 | 7.12% | 5,291 | 57.84 |
| Dr Reddys Laboratories | 105,255 | 18.27 | 33,741 | 16.73% | 5,725 | 46.16 |
| Lupin | 100,870 | 22.61 | 22,910 | 13.74% | 3,306 | 63.46 |
| Zydus Life Science | 94,229 | 18.63 | 23,511 | 18.55% | 4,615 | 54.52 |
| Mankind Pharma | 93,418 | 52.17 | 12,744 | 20.90% | 2,007 | 56.13 |
| Aurobindo Pharma | 73,030 | 20.91 | 32,346 | 9.43% | 3,484 | 60.21 |
| Alkem Laboratories | 69,192 | 28.04 | 13,458 | 3.70% | 2,216 | 55.49 |
Piramal Pharma Company Announcements - News Screener
Screen PPLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-17 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-12-17 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-12-11 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA Inspection | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2025-11-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-05 | Results - Financial Results For Quarter Ended September 30 2025 | View |
| 2025-11-05 | Board Meeting Outcome for Outcome Of Board Meeting Dated November 5 2025 | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-24 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September 2025. | View |
| 2025-10-16 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-09-30 | General - Update | View |
| 2025-09-09 | Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015 | View |
| 2025-09-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-08-25 | Sustainability Report - FY2024-25 | View |